Regional Content Customized for Canada
This page contains IO Essentials resources that have been customized for use by the Canadian healthcare professional.
This page contains IO Essentials resources that have been customized for use by the Canadian healthcare professional.
The document addresses
Developed in collaboration with Save Your Skin Foundation.
In the following videos, Massey Nematollahi, RN, MScN, OCN, CON©, Immuno-Oncology Clinical Nurse Specialist at William Osler Health System in Brampton, Ontario, discusses the use of COVID-19 vaccines in patients with cancer, particularly in those receiving immune checkpoint inhibitors (ICIs). The content is customised for the Canadian region. This content was recorded on August 20, 2021 and is reflective of the vaccine approvals as of that date. For an updated list of the currently available vaccines approved in Canada, please click here: Canada – COVID19 Vaccine Tracker (trackvaccines.org)
Review of available COVID-19 vaccines
Timing of receipt of vaccines
COVID-19 vaccines and ICIs
Addressing frequently asked questions and myths about COVID-19 vaccines
Addressing COVID-19 vaccine hesitancy
The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.
Developed in collaboration with Save Your Skin Foundation.
Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.
Developed in collaboration with Save Your Skin Foundation.
In the series of videos below, Massey Nematollahi, RN, MScN, OCN, CON©, Immuno-Oncology Clinical Nurse Specialist at William Osler Health System in Brampton, Ontario, shares perspectives and tips for optimising care during these challenging times.
Optimising Telemedicine
Use of Extended Dosing Intervals for Immunotherapy
Changes in Infusion Practices
Minimising the Impact on Clinical Trials
Educating Staff
Maintaining Patient Relationships Remotely
This section provides stand-alone Care Step Pathways (CSPs) that have been customized for the Canadian audience. We wish to thank Massey Nematollahi, RN, MScN,OCN, CON©, Immuno-Oncology Clinical Nurse Specialist at William Osler Health System in Brampton, Ontario, for thoughtful review of these materials.
For Immunotherapy (Checkpoint Inhibitors):
Ipilimumab
Nivolumab
Pembrolizumab
Nivolumab/Ipilimumab
This section contains the customizable action plans for patients with different tumor types that have been customized for the Canadian audience.